Evidence map›Paper›PMID 38196301›Full record

ArticleCancer medicine2024

Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.

Akito Hata, Simon Fifer, Kazuo Hasegawa, Emiko Ando, Mami Kasahara-Kiritani, Michiko Takahashi, Robyn Ordman, Lili Toh, Akira Inoue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Review
  3. Eight years, one patient.The oncologist · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akito HataDivision of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan.ORCID 0000-0001-7035-7249
Simon FiferCommunity and Patient Preference Research (CaPPRe), Sydney, Australia.
Kazuo HasegawaNPO Lung Cancer Patients Association One Step, Kanagawa, Japan.
Emiko AndoNPO Lung Cancer Patients Association One Step, Kanagawa, Japan.
Mami Kasahara-KiritaniIntegrated Market Access Division, Janssen Pharmaceutical K. K., Tokyo, Japan.
Michiko TakahashiMedical Affairs Division, Janssen Pharmaceutical K. K., Tokyo, Japan.
Robyn OrdmanCommunity and Patient Preference Research (CaPPRe), Sydney, Australia.
Lili TohCommunity and Patient Preference Research (CaPPRe), Sydney, Australia.ORCID 0000-0002-1329-1076
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, Sendai, Miyagi, Japan.

Funding

Janssen Pharmaceutical K. K.
6 · The paper itself

Abstract

introductionEvidence is limited on preferences of Japanese patients and physicians in treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Several oral or intravenous novel agents for EGFR exon 20 insertions are under development. The aim of our study was to investigate which attributes of novel treatments influenced selection of oral or intravenous agents among treated patients and treating physicians in Japan.

methodsThe study was designed by board-certified oncologists, patient representatives, and analytics specialists. Eligible participants completed an online survey with a discrete choice experiment presenting two treatment profiles described by attributes: mode of administration (oral or intravenous); frequency of administration; overall response rate (ORR); average progression-free survival (PFS); chance of experiencing severe side effects (SEs); mild-moderate gastrointestinal SEs; mild-moderate skin-related SEs; and patient out-of-pocket costs.

resultsFifty-four patients (all self-reported EGFR-mutant) and 74 physicians participated from December 2021 to August 2022. All attributes being equal, there was greater preference for oral administration. However, there was greater preference for intravenous over oral, when ORR and PFS improved by 10% and 1 month, and severe SEs reduced by 10%. Physicians exhibited greater preference for PFS compared to patients (p < 0.01). Ranked order of attribute importance was as follows: (1) PFS; (2) ORR; (3) severe SEs, expressed by patients and physicians alike.

conclusionsOur study revealed Japanese physician and patient preferences in treatment options for EGFR-mutant NSCLC. Compared to the strong preference for a more efficacious drug, the preference of oral versus intravenous revealed a smaller impact.

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationPatient PreferenceAdministration, IntravenousAdministration, OralAdultAgedAged, 80 and overAntineoplastic AgentsEast Asian PeopleFemaleHumansJapanMaleAntineoplastic AgentsEGFR protein, humanErbB Receptorsbioethicsgrowth factor receptorsinformed consentpalliative treatmentsocial movement against cancer

Identifiers

PMID38196301
PMCPMC10807555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.